ChemicalBook >> CAS DataBase List >>PF-04965842(Abrocitinib)

PF-04965842(Abrocitinib)

CAS No.
1622902-68-4
Chemical Name:
PF-04965842(Abrocitinib)
Synonyms
Abbrotinib;Abuxitinib;Abrocitinib;PF-04965842;2H7]-Abrocitinib;PF-04965842;ABROCITINIB;PF-04965842 >=98% (HPLC);ABROCITINIB (PF-04965842);PF-04965842;PF 04965842;PF04965842;PF-04965842; PF 04965842; PF04965842; ABROCITINIB
CBNumber:
CB14668353
Molecular Formula:
C14H21N5O2S
Molecular Weight:
323.41
MDL Number:
MFCD30187577
MOL File:
1622902-68-4.mol
MSDS File:
SDS
Last updated:2024-05-28 11:15:45

PF-04965842(Abrocitinib) Properties

Density 1.36±0.1 g/cm3(Predicted)
storage temp. room temp
solubility DMSO:100.0(Max Conc. mg/mL);309.2(Max Conc. mM)
pka 10.55±0.40(Predicted)
form powder
color white to beige
FDA UNII 73SM5SF3OR

SAFETY

Risk and Safety Statements

Symbol(GHS)  GHS hazard pictograms
GHS08
Signal word  Warning
Hazard statements  H361
Precautionary statements  P201-P202-P281-P308+P313-P405-P501
NFPA 704
0
2 0

PF-04965842(Abrocitinib) price More Price(11)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
ChemScene CS-0028460 Abrocitinib 99.79% 1622902-68-4 5mg $210 2021-12-16 Buy
ChemScene CS-0028460 Abrocitinib 99.79% 1622902-68-4 10mg $370 2021-12-16 Buy
Biorbyt Ltd orb573350 PF-04965842 (Abrocitinib) >98% 1622902-68-4 100mg $1133.9 2021-12-16 Buy
Biorbyt Ltd orb573350 PF-04965842 (Abrocitinib) >98% 1622902-68-4 250mg $2245.7 2021-12-16 Buy
AK Scientific 1496DY N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide 1622902-68-4 250mg $3165 2021-12-16 Buy
Product number Packaging Price Buy
CS-0028460 5mg $210 Buy
CS-0028460 10mg $370 Buy
orb573350 100mg $1133.9 Buy
orb573350 250mg $2245.7 Buy
1496DY 250mg $3165 Buy

PF-04965842(Abrocitinib) Chemical Properties,Uses,Production

Characteristics

Class: non-receptor tyrosine kinase
Treatment: atopic dermatitis
Oral bioavailability = 60%
Elimination half-life = 5 h
Protein binding = 50%

Biochem/physiol Actions

PF-04965842 is a Janus Kinase (JAK) inhibitor selective for JAK1 with an IC50 value of 29 nM for JAK1 compared to 803 nM for JAK2, >10000 nM for JAK3 and 1250 nM for Tyk2. JAKs mediate cytokine signaling, and are involved in cell proliferation and differentiation. PF-04965842 has been investigated as a possible treatment for psoriasis.

Mechanism of action

PF-04965842(Abrocitinib) is an orally bioavailable, selective  JAK1 inhibitor to treat moderate-to-severe atopic dermatitis. Abrocitinib preferentially blocks cytokine signaling involving JAK1 and is selective against signaling pathways using dual JAK2 or JAK2/TYK2.

Clinical Use

PF-04965842(Abrocitinib), a selective JAK1 inhibitor, was approved in 2022 for the treatment of adults with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug products or when the use of those therapies is inadvisable.

Metabolism

The oral absorption of abrocotinib is 91%, but its oral bioavailability is moderate (60%) due to hepatic metabolism.3,4 Human PK studies with oral administration of [14C]-abrocitinib showed that the parent drug was the most abundant circulating species (26%), along with 3 oxidative metabolites: PF-06471658 (11%), PF-07055087 (12%), and PF- 07054874 (14%). The two hydroxyl compounds are active metabolites, with comparable JAK1 selectivity profiles to abrocitinib, whereas the pyrrolidinone pyrimidine metabolite lacks in kinase activity. Based on the in vitro cytochrome P450 phenotyping studies in human hepatocytes, CYP2C19 and CYP2C9 are the major CYP isoforms involved in the oxidative metabolism of abrocitinib, contributing to 53% and 30% of overall metabolism, respectively. As abrocotinib is primarily cleared in the liver, impairment in hepatocellular function may affect its pharmacokinetic properties, which could potentially impact its safety and/or efficacy. Abrocitinib is quite lipophilic with logD (pH 7.4) value of 1.9, which contributes to a modest plasma protein binding of 64% in humans. Its terminal half-life of 5 h along with 60% oral bioavailability appears to be adequate for once-daily, oral treatment of moderate-to-severe atopic dermatitis.

PF-04965842(Abrocitinib) Preparation Products And Raw materials

Raw materials

Preparation Products

PF-04965842(Abrocitinib) Suppliers

Global( 144)Suppliers
Supplier Tel Email Country ProdList Advantage
shandong perfect biotechnology co.ltd
+86-53169958659; +8618596095638 sales@sdperfect.com China 294 58
Hangzhou ICH Biofarm Co., Ltd
+86-0571-28186870; +undefined8613073685410 sales@ichemie.com China 985 58
ATK CHEMICAL COMPANY LIMITED
+undefined-21-51877795 ivan@atkchemical.com China 32686 60
Jinan Carbotang Biotech Co.,Ltd.
+8615866703830 figo.gao@foxmail.com China 7154 58
BOC Sciences
+1-631-485-4226 inquiry@bocsci.com United States 19553 58
Qingdao kaimoshi biochemical technology co., ltd.
+86-0571-87191913 +86-19957014543 info@kaimosi.com CHINA 144 58
Career Henan Chemica Co
+86-0371-86658258 15093356674; laboratory@coreychem.com China 30255 58
NINGBOBENKANGJS PHARMTECHCO., LTD
+8615990591583 15990591583 CHINA 2029 58
HANGZHOU CLAP TECHNOLOGY CO.,LTD
86-571-88216897,88216896 13588875226 sales@hzclap.com CHINA 6313 58
Shanghai UCHEM Inc.
+862156762820 +86-13564624040 sales@myuchem.com China 6708 58

Related articles

View Lastest Price from PF-04965842(Abrocitinib) manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
Abrocitinib pictures 2024-03-12 Abrocitinib
1622902-68-4
US $0.00 / g 1g 98% HPLC 1kg shandong perfect biotechnology co.ltd
Abrocitinib pictures 2023-11-01 Abrocitinib
1622902-68-4
US $0.00-0.00 / kg 1kg 99.0% 20 tons Hangzhou ICH Biofarm Co., Ltd
  • Abrocitinib pictures
  • Abrocitinib
    1622902-68-4
  • US $0.00 / g
  • 98% HPLC
  • shandong perfect biotechnology co.ltd
  • Abrocitinib pictures
  • Abrocitinib
    1622902-68-4
  • US $0.00-0.00 / kg
  • 99.0%
  • Hangzhou ICH Biofarm Co., Ltd

PF-04965842(Abrocitinib) Spectrum

N-((1s,3s)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide 1-Propanesulfonamide, N-[cis-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)cyclobutyl]- PF-04965842 >=98% (HPLC) PF-04965842 Abrocitinib rel-N-((1s,3s)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide PF-04965842;PF 04965842;PF04965842 N-[cis-3-(Methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)cyclobutyl]-1-propanesulfonamide PF-04965842;ABROCITINIB ABROCITINIB (PF-04965842) PF-04965842; PF 04965842; PF04965842; ABROCITINIB Abbrotinib 2H7]-Abrocitinib N-[cis-3-[methyl({7H-pyrrolo[2,3-d]pyrimidin-4-yl})amino]cyclobutyl]propane-1-sulfonamide N-[(2S,3S,4S,6R)-6-[l(1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-2, 4-dihydro-1H-tetracen-1-yljoxy|-3-hydroxy-2-methyloxan-4-yll-2,2,2-trifluoroacetamide Abuxitinib 1622902-68-4 APIS api